Integra Lifesciences Holdings (IART) Cash from Investing Activities (2009 - 2026)

Integra Lifesciences Holdings has reported Cash from Investing Activities for 18 years, with the latest figure at -$43.3 million in Q2 2026.

• Quarterly Cash from Investing Activities fell 99.94% year-over-year to -$43.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$108.6 million (down 50.42% YoY) and the FY2025 annual result came in at -$108.1 million, up 72.35% from the prior year.
• Cash from Investing Activities slipped to -$43.3 million in Q2 2026 per IART's latest filing, from -$14.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $14.8 million in Q3 2022 and troughed at -$322.2 million in Q2 2024.
• A 5-year average of -$39.4 million and a median of -$15.6 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities jumped 274.69% in 2022, then slumped 1972.28% in 2024.
• Over 5 years, Cash from Investing Activities stood at -$54.8 million in 2022, then decreased by 4.39% to -$57.2 million in 2023, then jumped by 92.58% to -$4.2 million in 2024, then slumped by 721.53% to -$34.9 million in 2025, then retreated by 24.0% to -$43.3 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$43.3 million, -$14.8 million, and -$34.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.